People: Chr Hansen Holding A/S (CHRH.CO)
Mr. Thomas Schaefer has been Executive Vice President, Chief Scientific Officer, Research & Development and Member of the Executive Board at Chr. Hansen Holding A/S since November 1, 2017. He holds Ph.D. in Microbiology from Freie Universitaet Berlin, Germany. He has 23 years of experience from Novozymes. As a German national, Thomas Schaefer’s professional career started in 1994 where he joined the enzyme division of Novo Nordisk (in 2000 split into Novozymes) in Microbial Screening as a PostDoc. Throughout his years in Novozymes, he has held various senior positions primarily within R&D and Business Development. In 2013 Thomas Schaefer played a key role in making the BioAg Alliance with Monsanto a reality. This led to three years of expatriation in North Carolina, US, where he established Novozymes’ BioAg Application Research unit in RTP. Thomas Schaefer’s experience spans across both bacteria and enzymes under the umbrella of which he is further the co-inventor on a number of patents as well as publisher of several scientific papers and publications with WWF, WEF and the German Bioeconomy council. He is Member of the Board of the BioInnovation Institute and the Advisory Board for DTU Bioengineering.
|Total Annual Compensation, EUR||280,000|
|Restricted Stock Award, EUR||--|
|Long-Term Incentive Plans, EUR||30,000|
|All Other, EUR||--|
|Fiscal Year Total, EUR||310,000|